Cargando…

An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions

Cytotoxic therapeutic monoclonal antibodies (mAbs) often mediate target cell-killing by eliciting immune effector functions via Fc region interactions with cellular and humoral components of the immune system. Key functions include antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-depen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kinder, Michelle, Greenplate, Allison R, Strohl, William R, Jordan, Robert E, Brezski, Randall J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622058/ https://www.ncbi.nlm.nih.gov/pubmed/25933349 http://dx.doi.org/10.1080/19420862.2015.1022692

Ejemplares similares

IgG Fc engineering to modulate antibody effector functions
por: Wang, Xinhua, et al.
Publicado: (2017)

Current progress in innovative engineered antibodies
por: Strohl, William R.
Publicado: (2017)

Rational engineering of Fc/Fc receptor interactions to improve antibody potency
por: Doberstein, S, et al.
Publicado: (2003)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
por: Suzuki, Takuo, et al.
Publicado: (2021)

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
por: Trinklein, Nathan D., et al.
Publicado: (2019)

A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy
por: Fan, Xuejun, et al.
Publicado: (2012)

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
por: Aschmoneit, Nadine, et al.
Publicado: (2021)

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
por: Roßkopf, Sophia, et al.
Publicado: (2020)

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

Editorial: Antibody Fc Engineering: Towards Better Therapeutics
por: Lei, Cheng, et al.
Publicado: (2018)

Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
por: Wang, Lei, et al.
Publicado: (2013)

Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life
por: Mackness, Brian C., et al.
Publicado: (2019)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
por: Strohl, William R., et al.
Publicado: (2019)

Engineered human antibodies for the opsonization and killing of Staphylococcus aureus
por: Chen, Xinhai, et al.
Publicado: (2022)

B Cell-Based Seamless Engineering of Antibody Fc Domains
por: Hashimoto, Koji, et al.
Publicado: (2016)

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
por: Liu, Hongyan, et al.
Publicado: (2017)

Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
por: Escobar-Cabrera, Eric, et al.
Publicado: (2017)

Engineered Fc-glycosylation switch to eliminate antibody effector function
por: Zhou, Qun, et al.
Publicado: (2020)

Fc-engineered antibodies with immune effector functions completely abolished
por: Wilkinson, Ian, et al.
Publicado: (2021)

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
por: Abdeldaim, Dalia T., et al.
Publicado: (2023)

The Origins, Specificity, and Potential Biological Relevance of Human Anti-IgG Hinge Autoantibodies
por: Brezski, Randall J., et al.
Publicado: (2011)

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
por: Mimoto, Futa, et al.
Publicado: (2013)

Template directed synthesis of antibody Fc conjugates with concomitant ligand release
por: Postupalenko, Viktoriia, et al.
Publicado: (2022)

Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131)
por: Mimoto, F., et al.
Publicado: (2013)

A general Fc engineering platform for the next generation of antibody therapeutics
por: Chen, Da, et al.
Publicado: (2021)

Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
por: van Tetering, Geert, et al.
Publicado: (2020)

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
por: Liu, Rena, et al.
Publicado: (2020)

Fc-engineered antibody therapeutics with improved efficacy against COVID-19
por: Yamin, Rachel, et al.
Publicado: (2021)

Fc-engineered monoclonal antibodies to reduce off-target liver uptake
por: Mangeat, Tristan, et al.
Publicado: (2023)

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
por: Grugan, Katharine D., et al.
Publicado: (2016)

FcRn binding is not sufficient for achieving systemic therapeutic levels of immunoglobulin G after oral delivery of enteric‐coated capsules in cynomolgus macaques
por: Muzammil, Salman, et al.
Publicado: (2016)

Assessing the Heterogeneity of the Fc-Glycan of a Therapeutic Antibody Using an engineered FcγReceptor IIIa-Immobilized Column
por: Kiyoshi, Masato, et al.
Publicado: (2018)

Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models
por: Valente, Delphine, et al.
Publicado: (2020)

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
por: Dang, Kevin, et al.
Publicado: (2021)

9th Annual European Antibody Congress, November 11–13, 2013, Geneva, Switzerland
por: Reichert, Janice M, et al.
Publicado: (2014)

Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells
por: Richard, Jonathan, et al.
Publicado: (2021)

Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells
por: Huang, Shuyu, et al.
Publicado: (2022)

An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH
por: Liu, Yutong, et al.
Publicado: (2022)

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
por: Zhang, Di, et al.
Publicado: (2016)

Fc engineering of anti-Nectin-2 antibody improved thrombocytopenic adverse event in monkey
por: Oshima, Tsutomu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_na3ouqloslgfl3h7jtukgc3286